CN115803051A - 用于复发性呼吸道乳头状瘤病的疫苗及其使用方法 - Google Patents

用于复发性呼吸道乳头状瘤病的疫苗及其使用方法 Download PDF

Info

Publication number
CN115803051A
CN115803051A CN202180041036.2A CN202180041036A CN115803051A CN 115803051 A CN115803051 A CN 115803051A CN 202180041036 A CN202180041036 A CN 202180041036A CN 115803051 A CN115803051 A CN 115803051A
Authority
CN
China
Prior art keywords
nucleotide sequence
seq
nucleic acid
hpv11
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180041036.2A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬妮·拉莫斯
查尔斯·里德
朱厄尔·沃尔特斯
严健
安娜·斯莱格
凯特·布罗德里克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inovio Pharmaceuticals Inc
Original Assignee
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc filed Critical Inovio Pharmaceuticals Inc
Publication of CN115803051A publication Critical patent/CN115803051A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202180041036.2A 2020-05-14 2021-05-14 用于复发性呼吸道乳头状瘤病的疫苗及其使用方法 Pending CN115803051A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063024912P 2020-05-14 2020-05-14
US63/024,912 2020-05-14
PCT/US2021/032545 WO2021231925A1 (en) 2020-05-14 2021-05-14 Vaccines for recurrent respiratory papillomatosis and methods of using the same

Publications (1)

Publication Number Publication Date
CN115803051A true CN115803051A (zh) 2023-03-14

Family

ID=78513438

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180041036.2A Pending CN115803051A (zh) 2020-05-14 2021-05-14 用于复发性呼吸道乳头状瘤病的疫苗及其使用方法

Country Status (15)

Country Link
US (3) US11744885B2 (https=)
EP (1) EP4149536A4 (https=)
JP (2) JP7765407B2 (https=)
KR (1) KR20230011335A (https=)
CN (1) CN115803051A (https=)
AU (2) AU2021271860B2 (https=)
BR (1) BR112022022719A2 (https=)
CA (1) CA3177949A1 (https=)
CO (1) CO2022017989A2 (https=)
IL (1) IL297903A (https=)
MX (1) MX2022014248A (https=)
PE (1) PE20230349A1 (https=)
PH (1) PH12022553102A1 (https=)
SA (1) SA522441314B1 (https=)
WO (1) WO2021231925A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022022719A2 (pt) 2020-05-14 2023-02-14 Inovio Pharmaceuticals Inc Vacinas para papilomatose respiratória recorrente e métodos de usar a mesma
US11409951B1 (en) * 2021-09-24 2022-08-09 International Business Machines Corporation Facilitating annotation of document elements
CN114106207B (zh) * 2022-01-24 2022-04-26 诺未科技（北京）有限公司 Ccl5的用途
US20240123052A1 (en) * 2022-10-13 2024-04-18 Inovio Pharmaceuticals, Inc. Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same
CN121752584A (zh) * 2023-05-22 2026-03-27 普瑞赛格恩公司 用于治疗复发性呼吸道乳头状瘤病的新型腺病毒疫苗疗法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107267530A (zh) * 2009-01-23 2017-10-20 宾夕法尼亚大学托管会 改善的用于人乳头状瘤病毒的疫苗及其使用方法
TW201941786A (zh) * 2018-02-02 2019-11-01 南韓商Ｓｌ瓦西基因公司 一種新型多價hpv 疫苗成份

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3805783A (en) 1971-02-12 1974-04-23 A Ismach Hand powered hypodermic jet injector gun
US4342310A (en) 1980-07-08 1982-08-03 Istvan Lindmayer Hydro-pneumatic jet injector
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5505697A (en) 1994-01-14 1996-04-09 Mckinnon, Jr.; Charles N. Electrically powered jet injector
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
JP2002520101A (ja) 1998-07-13 2002-07-09 ジェネトロニクス、インコーポレーテッド 電気的に補助される化粧用薬剤の局部送達法および装置
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
US6520950B1 (en) 1999-05-10 2003-02-18 Genetronics, Inc. Method of electroporation-enhanced delivery of active agents
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
MXPA05004860A (es) 2002-11-04 2005-08-18 Advisys Inc Promotores musculares sinteticos con actividades que exceden las secuencias reguladoras de origen natural en las celulas cardiacas.
WO2014093894A2 (en) 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
AU2014248535B2 (en) 2013-03-12 2017-03-30 Inovio Pharmaceuticals, Inc. Improved vaccines for human papilloma virus and methods for using the same
KR20150130284A (ko) 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
MX2017007187A (es) 2014-12-01 2018-01-30 Univ Pennsylvania Construcciones de anticuerpos de adn y metodo para utilizarlas.
AU2016274655B2 (en) 2015-06-10 2021-06-17 NeoTrail Therapeutics, Inc. HPV vaccines
JP6920694B2 (ja) * 2015-12-04 2021-08-18 シアメン ユニバーシティＸｉａｍｅｎ Ｕｎｉｖｅｒｓｉｔｙ ヒトパピローマウイルスタイプ１１のｌ１タンパク質の突然変異
US20230000969A1 (en) 2019-10-24 2023-01-05 Inovio Pharmaceuticals, Inc. Improved vaccines for recurrent respiratory papillomatosis and methods for using the same
BR112022022719A2 (pt) 2020-05-14 2023-02-14 Inovio Pharmaceuticals Inc Vacinas para papilomatose respiratória recorrente e métodos de usar a mesma
CA3223587A1 (en) 2021-06-30 2023-01-05 Paul Fisher Side-port injection devices for use with electroporation, and related systems and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107267530A (zh) * 2009-01-23 2017-10-20 宾夕法尼亚大学托管会 改善的用于人乳头状瘤病毒的疫苗及其使用方法
TW201941786A (zh) * 2018-02-02 2019-11-01 南韓商Ｓｌ瓦西基因公司 一種新型多價hpv 疫苗成份

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘鹏, 李昂, 马军, 尚宁宽, 来宝长, 司履生, 王一理: "HPV-6/11 L1/E6、HPV-6/11 L1/E7嵌合DNA疫苗质粒的构建", 西安交通大学学报(医学版), vol. 24, no. 05, 31 October 2003 (2003-10-31), pages 413 - 442 *

Also Published As

Publication number Publication date
US20260053908A1 (en) 2026-02-26
US20210353736A1 (en) 2021-11-18
CO2022017989A2 (es) 2022-12-20
SA522441314B1 (ar) 2024-08-05
MX2022014248A (es) 2022-12-02
EP4149536A4 (en) 2024-08-07
BR112022022719A2 (pt) 2023-02-14
US11744885B2 (en) 2023-09-05
US20230414744A1 (en) 2023-12-28
AU2021271860A1 (en) 2022-12-15
JP2025158979A (ja) 2025-10-17
WO2021231925A1 (en) 2021-11-18
US12478667B2 (en) 2025-11-25
PE20230349A1 (es) 2023-03-02
EP4149536A1 (en) 2023-03-22
JP7765407B2 (ja) 2025-11-06
IL297903A (en) 2023-01-01
KR20230011335A (ko) 2023-01-20
AU2025220899A1 (en) 2025-09-18
WO2021231925A8 (en) 2022-03-24
AU2021271860B2 (en) 2025-06-05
CA3177949A1 (en) 2021-11-18
PH12022553102A1 (en) 2023-11-20
JP2023525558A (ja) 2023-06-16

Similar Documents

Publication Publication Date Title
AU2021271860B2 (en) Vaccines for recurrent respiratory papillomatosis and methods of using the same
US11124545B2 (en) Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
JP6153473B2 (ja) Ｂ型肝炎ウイルスコアタンパク質をコードする核酸分子およびそれを含むワクチン
US20240123052A1 (en) Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same
HK40089092A (zh) 用於复发性呼吸道乳头状瘤病的疫苗及其使用方法
EA049710B1 (ru) Вакцины против рецидивирующего респираторного папилломатоза и способы их применения
US20230340033A1 (en) Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use
HK40126944A (zh) 用於复发性呼吸道乳头状瘤病的疫苗及其使用方法
AU2018201443B2 (en) Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
WO2022174052A1 (en) Consensus prostate antigens, nucleic acid molecules encoding the same, and vaccines and uses comprising the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40089092

Country of ref document: HK